Lack of association between plasma Dehydroepiandrosterone Sulfate (DHEA-S) levels and depression in hemodialysis patients: A cross-sectional study

School of Medicine, Chang Gung University, Chang Gung Memorial Hospital, Keelung, Taiwan.
Experimental gerontology (Impact Factor: 3.49). 10/2009; 44(11):733-9. DOI: 10.1016/j.exger.2009.08.009
Source: PubMed

ABSTRACT Depression is common in hemodialysis patients. Reduced DHEA-S levels have been shown to be associated with depression in general population. Abnormalities in hormone production and metabolism are found in hemodialysis patients. However, the association between DHEA-S levels and depression in hemodialysis patients has not been established.
We conducted a cross-sectional study, in which 80 patients under regular hemodialysis were studied, and their serum DHEA-S levels were analyzed.
The prevalence of depression in our studied hemodialysis population is 37.5% (30/80). The DHEA-S level was 1138.1+/-1216.9 ng/mL in male patients and 502.1+/-389.4 ng/mL in female patients. The levels were not significantly different between patients with or without depression (910.8+/-1127.1 ng/mL vs. 769.3+/-848.3 ng/mL, P=0.533). As compared to the non-depressed patients, the depressed patients were more likely to be male, with lower body mass index, consuming more alcohol, and with more co-morbidity. The prevalence of depression was not associated with age, educational background, smoking, duration of dialysis, hemoglobin, albumin, CRP, ferritin, and urea clearance (Kt/V and URR). The serum DHEA-S levels exhibited significant and independent associations with age, gender, diabetes mellitus, and the levels of serum albumin.
The study suggested a lack of association between plasma DHEA-S levels and depression in hemodialysis patients.

21 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: Borderline personality disorder (BPD) patients display a complex and heterogeneous clinical phenotype that plausibly implies variable underlying pathogenic mechanisms. A dysregulation of peripheral benzodiazepine receptors has previously been shown in BPD peripheral tissues, implying possible alterations of its ligand, the diazepam binding inhibitor (DBI) or of the downstream products of its activation, i.e. neuroactive steroids. Methods: The aim of this work consisted in assessing, by ELISA, fasting plasma levels of DBI and dehydroepiandrosterone sulphate (DHEA-S), including cortisol and the cortisol-to-DHEA-S molar ratio (CDR), in 17 BPD adolescents versus 13 healthy controls, testing the possibility that clinical scales related to depressive or anxious traits (CDI, STAI-Y) or to disease severity (BPDCL) might be associated with a selective dysregulation of these parameters. Results: DBI plasma levels were unchanged, while DHEA-S ones were significantly increased (approx. 70%) and the CDR decreased in BPD patients. No meaningful correlations with clinical variables emerged. Conclusion: Our results indicate that a dysfunction of the neurosteroid system might be operative in BPD in spite of unchanged DBI plasma levels and that DHEA-S might represent a generalized trait marker for the altered stress response that is associated with this disorder.
    Neuropsychobiology 12/2013; 69(1):19-24. DOI:10.1159/000356227 · 2.26 Impact Factor